[go: up one dir, main page]

NO20045679L - Nye fysiologik aktive substanser - Google Patents

Nye fysiologik aktive substanser

Info

Publication number
NO20045679L
NO20045679L NO20045679A NO20045679A NO20045679L NO 20045679 L NO20045679 L NO 20045679L NO 20045679 A NO20045679 A NO 20045679A NO 20045679 A NO20045679 A NO 20045679A NO 20045679 L NO20045679 L NO 20045679L
Authority
NO
Norway
Prior art keywords
active substances
physiologically active
new physiologically
compounds
new
Prior art date
Application number
NO20045679A
Other languages
English (en)
Other versions
NO20045679D0 (no
Inventor
Jun Niijima
Mitsuo Nagai
Yoshihiko Kotake
Yoshio Fukuda
Regina Mikie Kanada
Takashi Nakashima
Masashi Yoshida
Toshio Tsuchida
Original Assignee
Mercian Corp
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercian Corp, Eisai Co Ltd filed Critical Mercian Corp
Publication of NO20045679D0 publication Critical patent/NO20045679D0/no
Publication of NO20045679L publication Critical patent/NO20045679L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser representert ved den følgende generelle formel (I) , farmasøytisk akseptable salter derav eller hydrater av de samme, hvori R3, R6, R7 og R21 er like eller forskjellige og hver representerer hydroksy, etc. På grunn av inhibering av angiogenese (særlig VEGF produksjon ved hypoksi), er forbindelsene (I) anvendbare som legemidler for fast cancer.
NO20045679A 2002-05-29 2004-12-28 Nye fysiologik aktive substanser NO20045679L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002155853 2002-05-29
JP2002223355 2002-07-31
JP2003063176 2003-03-10
PCT/JP2003/006779 WO2003099813A1 (fr) 2002-05-29 2003-05-29 Nouvelles substances physiologiquement actives

Publications (2)

Publication Number Publication Date
NO20045679D0 NO20045679D0 (no) 2004-12-28
NO20045679L true NO20045679L (no) 2005-02-28

Family

ID=29587471

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045679A NO20045679L (no) 2002-05-29 2004-12-28 Nye fysiologik aktive substanser

Country Status (17)

Country Link
US (4) US20060009439A1 (no)
EP (3) EP1508570A4 (no)
JP (2) JP4491341B2 (no)
KR (1) KR100954401B1 (no)
CN (2) CN1665807A (no)
AU (1) AU2003241927C1 (no)
BR (1) BR0311331A (no)
CA (1) CA2486728C (no)
ES (1) ES2603803T3 (no)
IL (2) IL165388A0 (no)
IS (1) IS7571A (no)
MX (1) MXPA04011885A (no)
NO (1) NO20045679L (no)
NZ (1) NZ536778A (no)
PL (1) PL373806A1 (no)
TW (1) TWI334866B (no)
WO (1) WO2003099813A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
AU2003252299A1 (en) 2002-07-31 2004-02-16 Eisai Co., Ltd. Novel physiologically active substance
KR20050086873A (ko) 2002-11-29 2005-08-30 메루샹가부시키가이샤 매크로라이드계 화합물의 제조 방법
US7932083B2 (en) 2003-11-27 2011-04-26 Mercian Corporation DNA participating in hydroxylation of macrolide compound
WO2005073223A1 (ja) * 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. マクロライド系化合物の安定化方法
EP1712642B1 (en) * 2004-02-06 2010-06-02 Eisai R&D Management Co., Ltd. Method of examining sensitivity of cancer cell to anticancer agent
EP1770165B1 (en) 2004-07-20 2011-12-21 Eisai R&D Management Co., Ltd. Dna coding for polypeptide participating in biosynthesis of pladienolide
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
US20090227795A1 (en) * 2006-08-02 2009-09-10 Eisai R & D Management Co., Ltd. Target molecules of pladienolides, compounds binding to such target molecules, and screening method thereof
AU2007285215A1 (en) * 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
EP2116542A4 (en) * 2007-01-29 2011-05-04 Eisai R&D Man Co Ltd SOLID OF A MAKROLIDE COMPOUND, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
US20100021918A1 (en) 2007-03-05 2010-01-28 Eisai R&D Management Co., Ltd. Method for assaying action of antitumor agent using splicing defects as index
JPWO2008111466A1 (ja) * 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) * 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
CN101730693A (zh) * 2007-07-06 2010-06-09 卫材R&D管理有限公司 大环内酯系化合物的制造方法及其制造中间体
GB0821539D0 (en) * 2008-11-25 2008-12-31 Merlion Pharmaceuticals Pte Ltd Therapeutic compounds and their use
JO3668B1 (ar) 2014-05-15 2020-08-27 Eisai R&D Man Co Ltd مركبات بلاديينوليد البيريدين وطرق استعمالها
EP3344780B1 (en) 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
RU2021102393A (ru) 2015-11-18 2021-03-17 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Твердые формы пладиенолидпиридиновых соединений и способы их применения
KR20190137810A (ko) 2017-03-15 2019-12-11 에자이 알앤드디 매니지먼트 가부시키가이샤 스플라이세오솜 돌연변이 및 그의 용도
US11926619B2 (en) * 2018-04-09 2024-03-12 Eisai R & D Management Co., Ltd. Certain pladienolide compounds and methods of use
CN112368270B (zh) 2018-04-12 2023-10-13 卫材R&D管理有限公司 作为用于治疗癌症的剪接体靶向剂的普拉二烯内酯衍生物
AU2019277700A1 (en) 2018-06-01 2020-11-19 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
MX2020012940A (es) 2018-06-01 2021-03-25 Eisai R&D Man Co Ltd Metodos de uso de moduladores de empalme.
RU195959U1 (ru) * 2019-09-23 2020-02-11 Анна Александровна Золотенкова Устройство для механической нейростимуляции языка
EP4161966A1 (en) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
US20240043928A1 (en) 2020-11-04 2024-02-08 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL27183A (en) 1966-02-01 1970-07-19 Upjohn Co Parenteral composition comprising freeze dried mannitol
JPS6054933B2 (ja) 1978-01-27 1985-12-03 小野薬品工業株式会社 プロスタグランジン及びプロスタグランジン類似化合物製剤の安定化法
JPH04352783A (ja) 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
AU685264B2 (en) 1994-04-25 1998-01-15 Kyowa Hakko Kogyo Co. Ltd. Method for stabilizing compound dx-52-1 and lyophilized composition thereof
CA2376010A1 (en) * 1999-06-03 2000-12-14 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Mycolactone and related compounds, compositions and methods of use
US6391903B1 (en) 1999-09-09 2002-05-21 Sankyo Company, Limited Triazole derivatives having antifungal activity
JP3240129B1 (ja) 1999-09-09 2001-12-17 三共株式会社 トリアゾール抗真菌剤
JP4953501B2 (ja) 1999-09-30 2012-06-13 大塚化学株式会社 ３−セフェム誘導体結晶の製造方法
AU2001278155A1 (en) 2000-08-03 2002-02-18 Kosan Biosciences, Inc. Fermentation and purification of mycolactones
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
TWI233361B (en) * 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
JP2004269488A (ja) 2002-06-06 2004-09-30 Hayashibara Biochem Lab Inc 結晶α−Ｄ−グルコシルα−Ｄ−ガラクトシドとこれを含有する糖質及びこれらの製造方法並びに用途
AU2003252299A1 (en) 2002-07-31 2004-02-16 Eisai Co., Ltd. Novel physiologically active substance
MXPA05001104A (es) * 2002-07-31 2005-09-08 Eisai Co Ltd Nuevas sustancias fisiologicamente activas.
KR20050086873A (ko) 2002-11-29 2005-08-30 메루샹가부시키가이샤 매크로라이드계 화합물의 제조 방법
US20050106275A1 (en) 2003-05-02 2005-05-19 Chen Su Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
CA2521928A1 (en) 2003-05-07 2004-11-18 Eisai Co., Ltd. Freeze-dried preparation containing methylcobalamin and process for producing the same
WO2005073223A1 (ja) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. マクロライド系化合物の安定化方法
JP2007269628A (ja) 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
JPWO2006075690A1 (ja) 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
EP1880994A4 (en) 2005-05-11 2010-04-14 Eisai R&D Man Co Ltd INDOLE DERIVED CRYSTAL COMPRISING A PIPERIDINE CYCLE AND PROCESS FOR SYNTHESIZING SAID CRYSTAL
CN101282967B (zh) * 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
AU2007285215A1 (en) 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
EP2116542A4 (en) * 2007-01-29 2011-05-04 Eisai R&D Man Co Ltd SOLID OF A MAKROLIDE COMPOUND, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH

Also Published As

Publication number Publication date
NZ536778A (en) 2007-03-30
CA2486728C (en) 2011-07-05
CN1665807B (zh) 2013-09-11
IS7571A (is) 2004-11-29
JP2010132693A (ja) 2010-06-17
EP2266978B1 (en) 2015-05-20
EP2927228B1 (en) 2016-09-07
AU2003241927A1 (en) 2003-12-12
US20060009439A1 (en) 2006-01-12
KR20050033552A (ko) 2005-04-12
US20080275059A1 (en) 2008-11-06
CN1665807A (zh) 2005-09-07
US7550503B2 (en) 2009-06-23
IL165388A (en) 2013-03-24
US20060241171A1 (en) 2006-10-26
AU2003241927B2 (en) 2009-06-18
CA2486728A1 (en) 2003-12-04
IL165388A0 (en) 2006-01-15
BR0311331A (pt) 2005-05-10
ES2603803T3 (es) 2017-03-01
EP1508570A1 (en) 2005-02-23
MXPA04011885A (es) 2005-09-12
AU2003241927C1 (en) 2009-11-05
JPWO2003099813A1 (ja) 2005-09-22
EP1508570A4 (en) 2007-08-15
AU2003241927B8 (en) 2009-07-23
US7893068B2 (en) 2011-02-22
WO2003099813A1 (fr) 2003-12-04
TWI334866B (en) 2010-12-21
PL373806A1 (en) 2005-09-19
EP2927228A1 (en) 2015-10-07
NO20045679D0 (no) 2004-12-28
US7619100B2 (en) 2009-11-17
KR100954401B1 (ko) 2010-04-26
US20080255146A1 (en) 2008-10-16
JP4491341B2 (ja) 2010-06-30
EP2266978A1 (en) 2010-12-29
TW200406408A (en) 2004-05-01

Similar Documents

Publication Publication Date Title
NO20045679L (no) Nye fysiologik aktive substanser
NO20092033L (no) Nye forbindelser
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20064576L (no) Pyrimidin-derivater for behandling av avvikende celle vekst
NO20050921L (no) Nye fysiologisk aktive substanser
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
NO20074703L (no) Antibakterielle piperidinderivater
NO20054852L (no) GFAT inhibitorer
NO20065904L (no) Terapeutiske forbindelser
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20090328L (no) Nye forbindelser 385
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
NO20066055L (no) Pyridinderivater
WO2007135527A3 (en) Benzimidazolyl compounds
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
NO20076138L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application